Eli Lilly, AstraZeneca announce continuation of clinical trial for AMARANTH
Monday, April 11, 2016
Eli Lilly and Company and AstraZeneca announce continuation of pivotal clinical trial for people with early Alzheimer's disease.
AMARANTH, in development as potential treatment for early alzheimer's disease, to continue to Phase 3 of Phase 2/3 seamless trial.
Says AstraZeneca will receive a milestone payment from Lilly now that AZDd3293 has moved into Phase 3 testing.
Says payment will result in Q2 charge of $100 million (pre-tax) to Lilly's GAAP and non-GAAP research and development expense.
Says Lilly and AstraZeneca have also announced planned initiation of a new Phase 3 trial for AZD3293.
Says DAYBREAK will begin enrolling participants in Q3 of 2016.
Source : reuters.com
